Sunshine Silver Mining & Refining saw its shares rise 27% during its debut on the New York Stock Exchange, signaling strong investor interest. AstraZeneca celebrated its transfer to the NYSE, noted as the largest by market capitalization in the exchange's 234-year history. Meanwhile, fintech company RedotPay introduced a new B2B product aimed at cutting global merchant fees by 70%. These developments highlight active market movements and innovation ahead of trading sessions.
Jefferies has reaffirmed its 'buy' rating on AstraZeneca, highlighting the upcoming late-stage trial results for its heart drug eplontersen (Wainua) as a major catalyst. The CARDIO-TTRansform phase III study targets transthyretin amyloidosis, with da...
More than 20 pharmaceutical companies are actively researching and developing over 25 drugs for acute kidney injury (AKI), a condition causing sudden kidney function decline. Key players like AstraZeneca and Akebia Therapeutics are advancing therapie...
The iShares Core MSCI EAFE ETF has gained about 10.5% year to date and 24% over the past year, benefiting from a weaker U.S. dollar and strong holdings in European and Japanese megacaps like ASML and major pharma companies. The fund's performance is ...
The 16th annual PODD (Partnership Opportunities in Drug Delivery) conference will take place on October 29-30, 2026, in Boston, gathering over 1,000 industry leaders to discuss advancements in drug delivery systems. The event features over 150 sessio...
The FTSE 100 rose modestly by 21 points to 10,459, supported by consumer defensive stocks like Bunzl and AstraZeneca, despite heavy losses in miners and tech funds. US and Asian tech stocks, including AI and semiconductor firms, sold off sharply, wit...
